A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants

  1. Jing Zhang
  2. Zi Bo Han
  3. Yu Liang
  4. Xue Feng Zhang
  5. Yu Qin Jin
  6. Li Fang Du
  7. Shuai Shao
  8. Hui Wang
  9. Jun Wei Hou
  10. Ke Xu
  11. Wenwen Lei
  12. Ze Hua Lei
  13. Zhao Ming Liu
  14. Jin Zhang
  15. Ya Nan Hou
  16. Ning Liu
  17. Fu Jie Shen
  18. Jin Juan Wu
  19. Xiang Zheng
  20. Xin Yu Li
  21. Xin Li
  22. Wei Jin Huang  Is a corresponding author
  23. Gui Zhen Wu  Is a corresponding author
  24. Ji Guo Su  Is a corresponding author
  25. Qi Ming Li  Is a corresponding author
  1. National Vaccine and Serum Institute, China
  2. Beijing Institute of Biological Products Company Limited, China
  3. Chinese Center For Disease Control and Prevention, China
  4. National Institutes for Food and Drug Control, China
1 additional file

Additional files

All additional files

Any figure supplements, source code, source data, videos or supplementary files associated with this article are contained within this zip.

https://cdn.elifesciences.org/articles/78633/elife-78633-supp-v1.zip

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jing Zhang
  2. Zi Bo Han
  3. Yu Liang
  4. Xue Feng Zhang
  5. Yu Qin Jin
  6. Li Fang Du
  7. Shuai Shao
  8. Hui Wang
  9. Jun Wei Hou
  10. Ke Xu
  11. Wenwen Lei
  12. Ze Hua Lei
  13. Zhao Ming Liu
  14. Jin Zhang
  15. Ya Nan Hou
  16. Ning Liu
  17. Fu Jie Shen
  18. Jin Juan Wu
  19. Xiang Zheng
  20. Xin Yu Li
  21. Xin Li
  22. Wei Jin Huang
  23. Gui Zhen Wu
  24. Ji Guo Su
  25. Qi Ming Li
(2022)
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
eLife 11:e78633.
https://doi.org/10.7554/eLife.78633